You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis

    SBC: GLYCOPATH INC            Topic: 400

    Lupus nephritis (LN), an immune complex-mediated glomerulonephritis, affects up to two-thirds of patients with systemic lupus erythematosus. Despite standard treatment protocols, progression of the most aggressive forms of LN (class III and IV) to end-stage renal failure remains high. Thus, there is a need for biomarkers of therapeutic response that would allow physicians to make better-informed t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Developing natural compound emodin as a therapy for alcoholic cardiomyopathy

    SBC: AcePre, LLC            Topic: NIAAA

    Project Summary: Alcoholic Cardiomyopathy (ACM) is the most prevalent form of ethanol-induced heart damage. Alcohol dose-dependently induces ACM, characterized by progressive reduction in myocardial contractility and ventricular dilatation, culminating in heart failure. At the cellular level, chronic alcohol consumption results in cardiomyocyte death, cardiac inflammation, and cardiac fibrosis. Th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development

    SBC: FIBROTHERAPEUTICS INC            Topic: NHLBI

    Abstract Our long-term objective is to fill the unmet need for treatments for heart failure (HF). Caveolin-1 is a promising therapeutic target in fibrotic diseases. The profibrotic effects of caveolin-1 deficiency in cells and in mouse models is suppressed by a peptide equivalent to its active site (caveolin-1 scaffolding domain, CSD). We have shown the beneficial effects of CSD in two independent ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis

    SBC: FibroBiologics, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of only 3 - 5 years from diagnosis. Although two FDA-approved drugs, pirfenidone and nintedanib, may slow the rate of decline of lung function in some IPF patients, neither drug significantly alters the course of this lethal disease. There is a great need for new drugs with greater efficacy and le ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Developing novel LOX inhibitors to target chemotherapy resistant TNBC

    SBC: LOXIGEN, INC.            Topic: 102

    PROJECT SUMMARY Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. It accounts for ~15% of all breast cancer yet is responsible for 30% of breast cancer deaths. TNBC is treated primarily by conventional chemotherapy; however, resistance to therapy is common, leading to high mortality rates. Importantly, the benefit of current therapeutic strategies used in chemoresi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.

    SBC: Zylo Therapeutics Inc.            Topic: NIAMS

    Project Summary/Abstract Approximately 500,000 people in the U.S. suffer from cutaneous lupus lesions (CLE), with a significant impact on quality of life.4 Yet, there is no cure, the treatment options are limited, and no new drug has been FDA- approved for over 50 years.84 As such, CLE represents a high unmet need for directed therapeutics. Skin lesions are caused by a complex autoimmune response ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Advanced Quantitative Magnetic Resonance Imaging Phantoms for Nonalcoholic Fatty Liver Disease

    SBC: CALIMETRIX LLC            Topic: NIBIB

    PROJECT SUMMARYThe overall goal of this Phase I proposal is to design and test the feasibility of novel magnetic resonance imaging (MRI) reference standards (“phantoms”) that are urgently needed for comprehensive and standardized quality assurance (QA) of quantitative MRI biomarkers of non-alcoholic fatty liver disease (NAFLD). We propose to develop 1) a quantitative MR elastography (MRE) stif ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Virtual Reality Technologies for Dynamic Balance Rehabilitation in People with Stroke

    SBC: KOBUK TECHNOLOGIES LLC            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT This project aims to quantify and establish elements of immersive virtual reality (VR) software that, when paired with treadmill training, produce balance perturbations that can be scaled to improve dynamic balance and are tolerated by people with stroke. VR continues to be used as an interactive and engaging way for clinicians to interact with patients during physical the ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A Framework for mHealth App Security and Privacy Analysis

    SBC: UBITRIX INTERNATIONAL, INC.            Topic: NLM

    PROJECT SUMMARY/ABSTRACT With the increased use of mobile health (mHealth) apps to improve health outcomes, protecting private health data is becoming increasingly important. These mHealth apps are offered by healthcare providers and used by patients for various reasons such as paying bills, scheduling appointments, sending messages to providers, accessing lab results, and viewing prescriptions an ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Neural organoid models of the immunological microenvironment of glioblastoma for drug discovery applications

    SBC: STEM PHARM, INCORPORATED            Topic: 102

    Project Summary/Abstract Glioblastoma (GBM) is the most prevalent primary brain tumor in adults with extremely poor survival rates and largely unchanged standard of care. While there are many challenges to developing better GBM treatments, one of the major challenges is the immune-suppressive environment commonly found within GBM tumors. This immune-suppressive nature results in a tumor that is no ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government